Redefining the unit economics of drug discovery for better patient outcomes
With an estimated 10⁶⁰ possible drug-like molecules, the chemical space is unimaginably large. And yet, drug discovery has only scratched its surface.
At Variational AI, we believe that the future of drug discovery lies not in screening molecules but in generating them. Using generative AI, we create novel, synthesizable small molecules optimized across multiple objectives such as potency, selectivity, and safety, without relying on massive screening libraries.
Our platform, Enki™, enables rapid exploration of uncharted chemical space — transforming the cost, speed, and scope of small molecule drug discovery, starting with oncology.
A simple workflow made to fit with your discovery process
From target product profile to synthesis-ready leads in weeks. Enki™ generates and optimizes novel compounds to meet selectivity, potency, toxicity, and pharmacokinetic goals.
1. Define the preclinical target product profile (TPP)
Specify the On/Off-targets and physico-chemical properties of the molecules as input for Enki™ generative AI.
2. Enki™ generates compounds
Enki™ generates novel and diverse structures that meet the defined TPP.
3. Make your selection
Pick compounds you want to synthesize and test. Enki™ can also perform hyper-efficient lead optimization while constrained to a defined scaffold.
Designed for early discovery
Purpose-built for early discovery, Enki™ helps generate first- and best-in-class compounds across multiple therapeutic areas
Generative AI, not screening
We generate new molecules de novo — freeing you from reliance on experimental or virtual libraries.
Multi-objective optimization
Enki™ simultaneously optimizes for more than 50 physico-chemical properties reflecting potency, selectivity, toxicity, PK, synthesizability and ADME.
Transforming drug discovery with AI
At Variational AI, we bring together machine learning researchers, chemists, and biotech professionals united by one mission: transforming early drug discovery with generative AI. Our cross-disciplinary team is always looking for new talents to push the boundaries of science and technology alongside us.
In the Press
Latest News
Applicability domains are common in QSAR but irrelevant for conventional ML tasks
Traditional QSAR models are limited to interpolation within known chemical spaces, restricting drug discovery. In contrast, modern machine learning excels at extrapolation, opening new possibilities for exploring untapped chemical compounds… Read More about Applicability domains are common in QSAR but irrelevant for conventional ML tasks
Variational AI announces generative AI project with Merck
Variational AI, developer of the Enki™ generative artificial intelligence (AI) platform for drug discovery, today announced a project with Merck Research Labs supported by the CQDM Quantum Leap program. Read More about Variational AI announces generative AI project with Merck
Variational AI Files Two US Provisional Patents for Potential COVID-19 Drug Created by Generative AI
Variational AI, developer of the Enki™ generative artificial intelligence (AI) drug discovery platform to redefine the economics of drug development, today announced that the company has filed two provisional patents… Read More about Variational AI Files Two US Provisional Patents for Potential COVID-19 Drug Created by Generative AI
Variational AI Adds Jennifer Hamilton as Advisor
Variational AI, developer of generative AI-based drug discovery platform for novel kinase inhibitors, today announced that it has added industry and scientific leader Jennifer Hamilton, Ph.D. as a company advisor. Read More about Variational AI Adds Jennifer Hamilton as Advisor
Upcoming Events
San DiegoVariational AI at Drug Discovery Chemistry 2026
Variational AI will participate in Drug Discovery Chemistry 2026, a premier conference for scientists focused on the discovery and optimization of small-molecule therapeutics. The event brings together medicinal, biophysical, and computational chemists from pharmaceutical companies,… Learn More about Variational AI at Drug Discovery Chemistry 2026
VancouverVariational AI to speak at ALL IN Talks West
Variational AI will participate in ALL IN Talks West, an event bringing together researchers, industry leaders, builders, and decision-makers focused on the practical deployment of artificial intelligence systems in real-world environments. “From World-Class Research to… Learn More about Variational AI to speak at ALL IN Talks West
TorontoVariational AI to Participate in the Bloom Burton Healthcare Investor Conference
Variational AI will participate in the Bloom Burton & Co. Healthcare Investor Conference (BBHIC), one of North America’s leading gatherings for healthcare investors and emerging life sciences companies. Meet with Variational AI Handol Kim, Co-Founder… Learn More about Variational AI to Participate in the Bloom Burton Healthcare Investor Conference